SPY314.84-2.75 -0.87%
DIA261.04+0.22 0.08%
IXIC10,390.84-226.60 -2.13%

B of A Securities Initiates Coverage On BridgeBio Pharma with Neutral Rating, Announces Price Target of $38

B of A Securities analyst Geoff Meacham initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Neutral rating and announces Price Target of $38.

Benzinga · -
B of A Securities analyst Geoff Meacham initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Neutral rating and announces Price Target of $38.